Indegene Limited

rs,

INDGN/SE/2025-26/62 October 02, 2025 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172 Dear Sir / Madam, Sub: Investor Pres

1.8 million

built over 2 decades spanning promotional response, claims, webinars, email, VSR, and programmatic (1.8 million and 3 million records) to give a broader, deeper view of HCP engagement Integrated Media Strategy,

3 million

des spanning promotional response, claims, webinars, email, VSR, and programmatic (1.8 million and 3 million records) to give a broader, deeper view of HCP engagement Integrated Media Strategy, Studio & Insi

100%

d analysis © 2025 Indegene. All rights reserved. 10 Transaction Details Transaction Structure: 100% ownership of BioPharm Parent Holding, Inc. along with its subsidiaries (BioPharm Communications LL

9.8x

ustment for any excess / deficit cash and working capital at closing Guaranteed payment: $77 Mn (~9.8x CY24 EBITDA / trailing basis) Upfront: $65 Mn paid at closing Deferred Payment: $12 Mn (Mar-26)

Transaction Structure

1

Source of Funds

1

Transaction Structure

100% ownership of BioPharm Parent Holding, Inc. along with its subsidiaries (BioPharm Communications LLC and Addressable Health LLC), collectively “BioPharm” Purchase Price: $104 Mn plus adjustment for any excess / deficit cash and working capital at closing Guaranteed payment: $77 Mn (~9.8x CY24 EBITDA / trailing basis) Upfront: $65 Mn paid at closing Deferred Payment: $12 Mn (Mar-26) Earnout 1: Upto $8 Mn (CY25 Performance) Earnout 2: Upto $19 Mn (CY26 Performance)